The NANOSPRESSO project is a pioneering response to the complex challenge of
treating orphan diseases, which, despite affecting millions of people globally, have
only scant therapeutic options. This initiative represents a paradigm shift by
decentralizing the production of personalized nucleic acid nanomedicines.
Integrating advanced microfluidic technology with lipid nanoparticle engineering
platforms—validated by their efficacy in COVID-19 messenger (m)RNA vaccines—
the NANOSPRESSO model enables hospital pharmacists to seamlessly assemble
tailored therapeutic cartridges for gene/RNA therapy administration at the patient’s
bedside. This innovative model subverts the traditional constraints of high-cost,
intricate manufacturing and the instability of nucleic acid-based treatments, offering
a streamlined. localized, flexible, and patient-centric alternative. Inspired by the
traditional art of compounding in pharmacy, NANOSPRESSO strives to democratize
access to innovative treatments for rare diseases, challenging the conventional,
monolithic medical approach.
Multifile
Not known
